Nancy Stuart - 13 Oct 2022 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Reporting relationship: Director
Issuer ticker: KALV
Reported as of: 13 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Oct 2022, 18:37:09 UTC
Prior SEC filing: 16 Feb 2022
Next SEC filing: 09 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Benjamin L. Palleiko, Attorney-in-Fact

Key filing fact

Nancy Stuart filed Form 4 for KalVista Pharmaceuticals, Inc. (KALV) on 17 Oct 2022.

Key facts

This page summarizes Nancy Stuart's Form 4 filing for KalVista Pharmaceuticals, Inc. (KALV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Oct 2022, 18:37.

Change

Previous filing in this sequence was filed on 16 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KALV transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 13 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $4.53
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests over a 12 month period: 1/12th on October 13, 2022, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.